Here's who's at the helm of the newly announced Texas Space Commission. Photo courtesy of the Office of the Governor

Governor Greg Abbott announced the Texas Space Commission, naming its inaugural board of directors and Texas Aerospace Research and Space Economy Consortium Executive Committee.

The announcement came at NASA's Johnson Space Center, and the governor was joined by Speaker Dade Phelan, Representative Greg Bonnen, Representative Dennis Paul, NASA's Johnson Space Center Director Vanessa Wyche, and various aerospace industry leaders.

According to a news release, the Texas Space Commission will aim to strengthen commercial, civil, and military aerospace activity by promoting innovation in space exploration and commercial aerospace opportunities, which will include the integration of space, aeronautics, and aviation industries as part of the Texas economy.

The Commission will be governed by a nine-member board of directors. The board will also administer the legislatively created Space Exploration and Aeronautics Research Fund to provide grants to eligible entities.

“Texas is home to trailblazers and innovators, and we have a rich history of traversing the final frontier: space,” Lieutenant Governor Dan Patrick says in a news release. “Texas is and will continue to be the epicenter for the space industry across the globe, and I have total confidence that my appointees to the Texas Space Commission Board of Directors and the Texas Aerospace Research and Space Economy Consortium Executive Committee will ensure the Texas space industry remains an international powerhouse for cutting-edge space innovation.”

TARSEC will independently identify research opportunities that will assist the state’s position in aeronautics research and development, astronautics, space commercialization, and space flight infrastructure. It also plans to fuel the integration of space, aeronautics, astronautics, and aviation industries into the Texas economy. TARSEC will be governed by an executive committee and will be composed of representatives of each higher education institution in the state.

“Since its very inception, NASA’s Johnson Space Center has been home to manned spaceflight, propelling Texas as the national leader in the U.S. space program,” Abbott says during the announcement. “It was at Rice University where President John F. Kennedy announced that the U.S. would put a man on the moon—not because it was easy, but because it was hard.

"Now, with the Texas Space Commission, our great state will have a group that is responsible for dreaming and achieving the next generation of human exploration in space," he continues. "Texas is the launchpad for Mars, innovating the technology that will colonize humanity’s first new planet. As we look into the future of space, one thing is clear: those who reach for the stars do so from the great state of Texas. I look forward to working with the Texas Space Commission, and I thank the Texas Legislature for partnering with industry and higher education institutions to secure the future of Texas' robust space industry."

The Houston-area board of directors appointees included:

  • Gwen Griffin, chief executive officer of the Griffin Communications Group
  • John Shannon, vice president of Exploration Systems at the Boeing Company
  • Sarah "Sassie" Duggleby, co-founder and CEO of Venus Aerospace
  • Kirk Shireman, vice president of Lunar Exploration Campaigns at Lockheed Martin
  • Dr. Nancy Currie-Gregg, director of the Texas A&M Space Institute

Additionally, a few Houstonians were named to the TARSEC committee, including:

  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace
  • Matt Ondler, president and former chief technology officer at Axiom Space
  • Jack “2fish” Fischer, vice president of production and operations at Intuitive Machines
  • Brian Freedman, president of the Bay Area Houston Economic Partnership and vice chairman of Wellby Financial
  • David Alexander, professor of physics and astronomy and director of the Rice Space Institute at Rice University

To see the full list of appointed board and committee members, along with their extended bios, click here.

This week's roundup of Houston innovators includes Sarah "Sassie" Duggleby of Venus Aerospace, Youngro Lee of Brassica, and Le Dam of myAvos. Photos courtesy

3 Houston innovators to know this week

WHO'S WHO

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from rocket science to fintech — recently making headlines in Houston innovation.

Sarah "Sassie" Duggleby, CEO and co-founder of Venus Aerospace

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby and her husband were living in Japan and considering a trip back to Texas and wishing there was a faster option than a full day of international travel — with their kids, no less. That's when Andrew Duggleby told Sassie that there actually might be an engine that could do that.

Flash forward a few years, and the husband-wife team has built a company around that idea. Venus Aerospace, originally founded in California, relocated to Houston in 2021 to establish their company in an ecosystem with the tools to advance their tech — and give their employees a good work-life balance, Sassie Duggleby explains on the Houston Innovators Podcast.

"We knew we had to find a location where we could test our engine and still be home for dinner," she says on the show. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner." Read more.

Youngro Lee has announced funding for his latest fintech endeavor. Photo courtesy

Youngro Lee is no stranger to shaking up the finance world with a new tech-based way of doing business. One of the founders of NextSeed, Lee's newest mission is providing "investment infrastructure as a service" with his company, Brassica, which just raised $8 million in seed funding.

“The future of finance will depend on the ability of trustworthy institutions to provide secure and seamless transitions between traditional financial services and web3 innovations while complying with strict regulations and still providing great customer experience,” says Lee in the news release.

Houston-based Mercury Fund led the round with several other investors participating. Read more.

Le Dam, CEO and founder of OptiChroniX

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

After years on the West Coast, Le Dam has returned to her adopted hometown of Houston — just in time to launch a new app dedicated to providing health resources and information to its users.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. Read more.

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Female Houston founder on her dream of making high-speed, international travel a reality

HOUSTON INNOVATORS PODCAST EPISODE 181

Sarah "Sassie" Duggleby is on a mission to get people home in time for dinner — whether they are traveling around the world or working for her business. That's why she founded Venus Aerospace, which is developing hypersonic space planes. It's also why she relocated the company from the West Coast to Houston.

"We knew we had to find a location where we could test our engine and still be home for dinner," Duggleby says on this week's episode of the Houston Innovators Podcast. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner."

Venus's technology enables this revolutionary travel through its supersonic combustion engine — more akin to a rocket's engine than an airplane's — that allows for travel at a higher elevation, she explains on the show. Jet engines rely on air outside of the aircraft to combust, and rocket engines work with a system that supplies air internally. And, as Duggleby explains, the engine can go further with the same amount of fuel, so it's a more sustainable way of traveling too.

"Our ultimate goal is to go with completely carbon-free propellants. There are fuel choices we could make that would be carbon free, but the biggest challenge is continuous operability," she says, explaining that there would then need to be green fuels at whatever airport Venus aircrafts land in to refuel. "You've got to stand up an entirely green ecosystem across the globe. But I think the world would handle that."

The company's developed engine right now works with jet fuel and hydrogen peroxide, a source that can be made without any carbon emissions, she says.

Duggleby founded Venus Aerospace with her husband and CTO Andrew in 2020. The two worked for Virgin Orbit before leaving to start Venus, relocating to Houston in 2021 and setting up shop in a hangar at Ellington Field in the Houston Spaceport. Last year, Venus raised a $20 million series A round.

Once a scrappy team of three people, Venus Aerospace now has almost 100 employees. When thinking about the challenges she's facing, Duggleby says she knows how to navigate the engineering journey the technology faces and she knows they face regulatory obstacles ahead too. Something Duggleby, recently named to Inc. magazine's Female Founders list, is focused on these days — with the pace of growth at the company — is staying true to the company culture she founded since day one.

"There's a constant tension to grow, grow, grow, and build out bigger systems, versus take what you have now and get it really great," she says on the show, recognizing that aerospace work environments tend to have more toxic and competitive cultures. "As important as the technology that we're building is, it's also just as important who we are and how we treat our people."

Duggleby shares more of her story on the podcast, as well as her observations on the space tech industry, Houston's role in the ecosystem, and more. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”